secwatch.observer — SEC 8-K summary
======================================

Issuer:     Athenex, Inc. (—)
CIK:        0001300699
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001193125-22-289550
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athenex closes sale of China API business for ~$18M; enters supply agreement
----------------------------------------------------------------------------

- Sold equity interests in China API manufacturing to Chongqing Comfort Pharmaceutical for ~$18M gross.
- Received ~$11M net at closing; remaining proceeds due in two tranches over six months.
- Entered long-term supply agreement for APIs used in Klisyri (tirbanibulin) and oral paclitaxel.
- Also received waiver from lenders waiving mandatory prepayment of Credit Agreement upon sale closing.
- CEO states completion demonstrates progress on monetizing non-core assets to focus on NKT cell therapy pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1300699/000119312522289550/0001193125-22-289550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1300699/000119312522289550/d370439d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-289550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer